Formation Bio has launched a $600 million fund to acquire and advance 10–15 clinical-stage drug programmes over the next three to five years.

Formation Bio, an AI-native pharmaceutical company, has announced $600 million in capital commitments for a new fund designed to expand its portfolio of clinical-stage medicines.

The Formation Bio Drug Development Accelerator Fund will finance the acquisition and development of drug programmes, combining dedicated investment with the company’s existing clinical and operational infrastructure.

The company plans to acquire or in-license Phase 1 and Phase 2 drug candidates from pharmaceutical companies and biotechnology businesses, prioritising programmes with a clear path to clinical proof of concept.

Formation Bio expects the fund to support the acquisition of 10–15 programmes over the next three to five years.

A different model for drug development

The fund will operate through a hub-and-spoke model, with each funded drug programme housed in a standalone corporate entity. Formation Bio will provide the development expertise and infrastructure needed to advance the assets, while keeping the finances of individual programmes separate.

The structure is intended to reduce the need for each programme to establish its own operating infrastructure, allowing more capital to be directed towards clinical development.

Formation Bio will act as the fund’s general partner through a wholly owned subsidiary and has committed its own capital alongside limited partners. These investors include research foundations, institutional endowments, hospitals and philanthropic organisations, although the company has not named individual investors.

Benjamine Liu, co-founder and CEO of Formation Bio, said: “This Fund gives our LPs access to an important and emerging investment category—individual drug assets—through a capital-efficient structure.”

Liu added that the fund would give Formation Bio greater flexibility to pursue drug candidates, create potential routes to liquidity without selling the parent company and potentially lower its cost of capital over time.

Targeting clinical milestones

Formation Bio focuses on drug candidates addressing diseases with substantial unmet medical need but limited active development across the industry.

Depending on the programme, the company aims to reach major clinical milestones within two to four years of acquisition. Funding will be allocated according to individual development requirements, allowing the company to concentrate resources on programmes it considers the most promising.

Following meaningful clinical progress, Formation Bio expects to partner programmes with pharmaceutical companies for commercialisation or co-commercialisation.

David Steinberg, chief business officer at Formation Bio, said: “As a biotech investor and founder, I’ve seen firsthand how promising medicines can get stranded in company pipelines.”

The fund is intended to provide another route for advancing such candidates, using Formation Bio’s development capabilities rather than requiring each asset to operate as an independent drug development business.

AI supports the development strategy

Formation Bio combines pharmaceutical and clinical expertise with proprietary technology and AI systems designed to support drug development.

Michael Ehlers, chief scientific officer and head of R&D at Formation Bio, said: “Few applications of AI have the potential to deliver as profound an impact on society as accelerating the development of new medicines.”

The company expects to build on its technology and operational capabilities as its portfolio expands, with the aim of creating efficiencies across subsequent development programmes.

However, the announcement does not identify the first drug candidates to be financed through the fund or provide clinical data demonstrating the impact of its AI systems on development outcomes.

The $600 million commitment establishes a substantial funding pool for Formation Bio’s acquisition-led strategy, with its success ultimately depending on the clinical progress of the medicines it selects.